- Home
- FSP vs IPHA Comparison
FSP vs IPHA Comparison
Compare FSP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSP
- IPHA
- Stock Information
- Founded
- FSP 1981
- IPHA 1999
- Country
- FSP United States
- IPHA France
- Employees
- FSP N/A
- IPHA N/A
- Industry
- FSP Real Estate Investment Trusts
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FSP Real Estate
- IPHA Health Care
- Exchange
- FSP Nasdaq
- IPHA Nasdaq
- Market Cap
- FSP 187.5M
- IPHA 148.3M
- IPO Year
- FSP N/A
- IPHA 2019
- Fundamental
- Price
- FSP $1.83
- IPHA $1.77
- Analyst Decision
- FSP
- IPHA Strong Buy
- Analyst Count
- FSP 0
- IPHA 1
- Target Price
- FSP N/A
- IPHA $11.50
- AVG Volume (30 Days)
- FSP 289.6K
- IPHA 42.3K
- Earning Date
- FSP 02-24-2025
- IPHA 09-12-2024
- Dividend Yield
- FSP 2.18%
- IPHA N/A
- EPS Growth
- FSP N/A
- IPHA N/A
- EPS
- FSP N/A
- IPHA N/A
- Revenue
- FSP $126,508,000.00
- IPHA $36,202,722.00
- Revenue This Year
- FSP N/A
- IPHA N/A
- Revenue Next Year
- FSP $0.02
- IPHA $101.65
- P/E Ratio
- FSP N/A
- IPHA N/A
- Revenue Growth
- FSP N/A
- IPHA N/A
- 52 Week Low
- FSP $1.47
- IPHA $1.29
- 52 Week High
- FSP $2.58
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- FSP 47.79
- IPHA 47.27
- Support Level
- FSP $1.82
- IPHA $1.65
- Resistance Level
- FSP $1.90
- IPHA $1.87
- Average True Range (ATR)
- FSP 0.06
- IPHA 0.10
- MACD
- FSP 0.00
- IPHA -0.02
- Stochastic Oscillator
- FSP 66.67
- IPHA 50.70
About FSP Franklin Street Properties Corp.
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The company's operations include rental income from real estate leasing, interest income from secured loans made on office properties, property dispositions, and fee income from asset/property management and development. Franklin Street markets Atlanta, Dallas, Denver, Houston, and Minneapolis.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.